![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Grants Fast-Track to Potential Heart Failure Drug
FDA Grants Fast-Track to Potential Heart Failure Drug
May 11, 2020
The FDA granted fast-track designation for an investigational heart failure treatment being developed by Amgen and Cytokinetics.
Omecamtiv mecarbil is currently in phase 3 testing for reducing the risk of cardiovascular death in patients with heart failure.
The novel investigational drug is designed to activate myosin, a protein in heart muscle that helps produce a heartbeat.
Upcoming Events
-
21Oct